Diethyltoluamide (DEET) is an insect repellent used to keep insects away. This product is effective against mosquitoes, biting flies (gnats, sandflies, deer flies, stable flies, black flies), ticks, harvest mites, and fleas. DEET is absorbed through the skin. DEET has few adverse effects when applied as directed. The most common problem is local skin irritation, including erythema and pruritis, at the site of application.

Perflunafene is a perfluorocarbon that can absorb, transport, and release oxygen and carbon dioxide. Perflunafene is a can be used as an alternative to red blood cell preparations to improve gaseous transport, in particular oxygen supply, to the tissues. Intra-ocular injection of perflunafene is used to provide temporary tamponade in ophthalmic procedures such as retinal re-attachment. Perflunafene and perfluamine have been used together for their oxygen-carrying properties in blood substitute preparations and to prevent myocardial ischaemia during percutaneous transluminal coronary angioplasty.

Ethacridine (Rivanol) is an acridine derivative indicated for the treatment of bacterial infections. In many countries the drug was in clinical practice for the second trimester termination of pregnancy.

Avilamycin is an orthosomycin antibiotic complex produced by the fermentation of Streptomyces viridochromogenes. Avilamycin is intended for use as a veterinary medicine in chickens, turkeys, pigs and rabbits to control bacterial enteric infections. It exhibits good antimicrobial activity against important veterinary Gram-positive pathogens (e.g., Clostridium perfringens) and has no related molecules in its class in human use. Therefore, avilamycin has been developed for treating necrotic enteritis in poultry, and enteric disease in pig and rabbits. Avilamycin inhibits bacterial protein synthesis through a novel mechanism of action by binding to the 50S ribosomal subunit and preventing the association of IF2, which inhibits the formation of the mature 70S initiation complex, and the correct positioning of tRNA in the aminoacyl site. No adverse drug-related changes were observed.